Role of Ghrelin Hormone in Systemic Lupus Erythematosus: Relation to Interferon alpha and Disease Activity Biomarkers | ||||
Egyptian Journal of Rheumatology and Clinical Immunology | ||||
Article 14, Volume 2, Issue 1, January 2014, Page 89-96 PDF (219.29 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/ejrci.2014.10428 | ||||
View on SCiNiTO | ||||
Authors | ||||
Amira Barakat1; Ehab Eltoraby1; Dina Shahin1; Adel Abdelsalam1; Moustafa Abdelsalam1; Noha Shaat2; Ayman Alsamanoudy3 | ||||
1Department of Internal Medicine, Mansoura University; Egypt | ||||
2Department of Rheumatology & Rehabilitation, Mansoura University; Egypt | ||||
3Department of Biochemistry, Mansoura University; Egypt | ||||
Abstract | ||||
Background: SLE is an autoimmune multisystem disease which results from both genetic predisposition and environmental factors. Ghrelin polypeptide is the natural ligand for the growth hormone secretagogue receptor exerts multiple immune regulatory effects as well as cardiovascular, metabolic and renal effects. On the other hand it was reported that some patients who have received recombinant human INF- injections to treat chronic viral infections or malignancy have developed de novo SLE which resolves with discontinuation of IFN- therapy. Our study was conducted to evaluate levels of ghrelin and INF- in SLE patients, their relation to different clinical manifestations of the disease and their correlation with disease activity markers in such patients. Methods: Fifty four SLE patients and 46 age and sex matched control healthy subjects were included in this study. Both ghrelin hormone and INF- were measured for all the studied groups using enzyme linked immune sorbent assay (ELISA) kit. We compare serum levels between SLE patients and control subjects also serum levels were correlated to different clinical manifestations and disease activity markers. Results: In this study we found significant increase in ghrelin hormone level in patients with lupus nephritis (p =0,0004) also it positively correlated with SLEDAI (p<0.0001), INF (r=0.3 & p<0.01), ANA (p<0.0001), dsDNA (p<0.002) and LDL (p=0.03) but there was negative correlation between ghrelin and both body weight and HDL. On the other hand there was no significant change in ghrelin hormone level in SLE patients with mucocutaneous manifestations, articular involvement, Cerebritis, serositis, vasculitis and constitutional symptoms. Conclusion: These data suggest the possible role for ghrelin hormone in the clinical manifestation of SLE patients especially those with lupus nephritis as well as the synchronization of both ghrelin and INF in the pathogenesis of SLE and their role in disease activity. [ | ||||
Keywords | ||||
SLE; ghrelin; interferon alpha | ||||
Statistics Article View: 341 PDF Download: 245 |
||||